Given a recent update from the PLCO trial reporting that over 90% of men in the 'usual care' arm underwent some degree of PSA testing, the PLCO can no longer accurately be called a trial of screening versus no screening — nor can it be included as such in meta-analyses or guideline statements.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Andriole, G. L. et al. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 360, 1310–1319 (2009).
Moyer, V. A. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 157, 120–134 (2012).
Schröder, F. H. et al. Screening and prostate- cancer mortality in a randomized European study. N. Eng. J. Med. 360, 1320–1328 (2009).
Lamerato, L. E., Marcus, P. M., Jacobsen, G. & Johnson, C. C. Recruitment in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial: the first phase of recruitment at Henry Ford Health System. Cancer Epidemiol. Biomarkers Prev. 17, 827–833 (2008).
Grubb, R. L. et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int. 102, 1524–1530 (2008).
Ilic, D., Neuberger, M. M., Djulbegovic, M. & Dahm, P. Screening for prostate cancer. Cochrane Database Syst. Rev. 1, CD004720 (2013).
Pinsky, P. F. et al. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin. Trials 7, 303–311 (2010).
Andriole, G. L. et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J. Natl Cancer Inst. 104, 1–8 (2012).
Shoag, J. E., Mittal, S. & Hu, J. C. Reevaluating PSA testing rates in the PLCO trial. N. Engl. J. Med. 374, 1795–1796 (2016).
Jemal, A. et al. Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA 314, 2054–2061 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Cooperberg, M. Why the prostate arm of the PLCO trial failed and what it has taught us. Nat Rev Urol 13, 439–440 (2016). https://doi.org/10.1038/nrurol.2016.116
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2016.116
